Total Funding
74
92
Total FundingPost-IPO Equity raised
Growth Score
4 pts
Heat Score
17 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
12448
AIM ImmunoTech is an immuno-pharmaceutical company that focuses on developing therapeutics that treat cancer and immunodeficiency disorders.
Robert Dickey: Chief Financial OfficerPast Role: Locus Pharmaceuticals, VP, Finance and CFO
About the Company
AIM ImmunoTech is an immuno-pharmaceutical company based in Ocala, Florida. Its expertise is in the development of therapeutics for treating cancers and immune-deficiency disorders. As a result, they have developed strong laboratory and clinical data in relation to the development of nucleic acids and natural interferon to enhance the natural
antiviral defence system of the human body and aid in the development of therapeutic products designed to treat cancer and chronic diseases. The company is committed to finding co-development partners with the capital and expertise to commercialize the many potential therapeutic aspects of Ampligen.
